Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899749 | 0.86 | SLC6A4 (0.40) | GRM2GRM3 | |
| SCHEMBL5899598 | 0.85 | TAAR1 (0.40) | CTBP2GRM2GRM3 | |
| SCHEMBL5899686 | 0.85 | GRM2 (0.34) | GRM2GRM3 | |
| SCHEMBL5899610 | 0.83 | SLC1A1 (0.41) | TRPA1GRM2GRM3 | |
| SCHEMBL5899751 | 0.80 | DPP4 (0.37) | GRM2GRM3 | |
| SCHEMBL5899791 | 0.80 | TRPA1 (0.40) | TRPA1 | |
| SCHEMBL5899618 | 0.78 | EPHX1 (0.35) | GRM2GRM3EPHX2 | |
| SCHEMBL5899706 | 0.77 | TAAR1 (0.39) | — | |
| SCHEMBL5899615 | 0.75 | KDM1A (0.44) | — | |
| SCHEMBL5899736 | 0.74 | FFAR4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | TRPA1 230/4885CTBP2 1263/4885GRM2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.